Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shravan Ambati

Clinical Cardiac Electrophysiology Orlando, FL Medical Doctor

NPI 1104985290 CMS profile 322981

11616 Lake Underhill Rd Ste 215, Orlando, FL 32825

Open in the dashboard

General payments

$161,309

777 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$204,695 paid to institutions, not to them · program years 2020–2023

Through program year 2025, Shravan Ambati of Orlando, FL is reported in the CMS Open Payments database as having received $161,309 across 777 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $204,695 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,226 95
2024 General $43,085 118
2023 General $19,230 143
2022 General $23,331 126
2021 General $16,857 109
2020 General $8,467 47
2019 General $30,112 139

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shravan Ambati
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Shravan Ambati were reported at $20,226. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Shravan Ambati Clinical Cardiac Electrophysiology median Middle half National median
2019 $30,112 $2,361 $585–$8,260 $163
2020 $8,467 $993 $247–$4,351 $114
2021 $16,857 $1,185 $326–$4,739 $132
2022 $23,331 $2,073 $554–$6,789 $149
2023 $19,230 $2,568 $759–$8,159 $160
2024 $43,085 $2,557 $703–$7,403 $164
2025 $20,226 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $38,979 85 payments
  2. Biotronik Inc. $28,022 128 payments
  3. Abbott Laboratories $21,940 109 payments
  4. AngioDynamics, Inc. $18,745 1 payment
  5. E.R. Squibb & Sons, L.L.C. $14,738 15 payments
  6. Novartis Pharmaceuticals Corporation $7,827 70 payments
  7. Lilly USA, LLC $7,719 7 payments
  8. Boston Scientific Corporation $5,476 35 payments
  9. Medtronic, Inc. $3,932 48 payments
  10. Pfizer Inc. $2,456 33 payments
  11. Other $11,476 246 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $66,095 32 payments
  2. Consulting Fee $32,802 56 payments
  3. Food and Beverage $26,780 631 payments
  4. Debt forgiveness $18,745 1 payment
  5. Travel and Lodging $15,115 51 payments
  6. Honoraria $1,500 1 payment
  7. Entertainment $223 1 payment
  8. Education $49 4 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $21,834 58 payments
  2. Auryon Atherectomy Catheter 1.5 mm OTW $18,745 1 payment
  3. JARDIANCE Diabetes $17,042 22 payments
  4. ELIQUIS $14,693 12 payments
  5. JARDIANCE Diabetes $7,700 6 payments
  6. Edora $7,605 31 payments
  7. ENTRESTO $7,511 43 payments
  8. Rivacor $6,805 30 payments
  9. Acticor $6,805 30 payments
  10. Acticor 7 VR-T DX $3,955 18 payments
  11. Other $65,293 614 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

6,451

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,620,659

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

35.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 499 $612,484
Jardiance Empagliflozin Brand 348 $405,525
Entresto Sacubitril/Valsartan Brand 212 $278,642
Xarelto Rivaroxaban Brand 76 $79,512
Farxiga Dapagliflozin Propanediol Brand 52 $53,763
Ozempic Semaglutide Brand 44 $51,369
Brilinta Ticagrelor Brand 73 $48,903
Amiodarone Hcl Generic 226 $8,945
Repatha Syringe Evolocumab Brand 14 $8,722
Metoprolol Succinate Generic 507 $6,783

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$342,047

Of which drugs: $3,840

Medicare patients

518

Average age 78

Services billed

4,093

272 women, 246 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 69%
Diabetes 57%
Heart failure 57%
Atrial fibrillation 57%
Chronic kidney disease 54%
Arthritis 46%
COPD 36%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 43 172 $1,142

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$14,469 348 —
LEQVIO
$120 — —
ELIQUIS
$93 499 —
ONPATTRO
$77 — —
FARXIGA
$64 52 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

777 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record